Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
Eligible for screening study DCP 001
S2212 is closed to accrual to the PRO Sub-Study, effective August 6, 2026.
